Compare BSAC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSAC | GH |
|---|---|---|
| Founded | 1977 | 2011 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 13.3B |
| IPO Year | 2002 | 2018 |
| Metric | BSAC | GH |
|---|---|---|
| Price | $34.96 | $91.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 19 |
| Target Price | $33.00 | ★ $119.79 |
| AVG Volume (30 Days) | 384.7K | ★ 2.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $37.15 | $33.30 |
| Revenue Next Year | $7.52 | $28.27 |
| P/E Ratio | $14.40 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $22.77 | $36.36 |
| 52 Week High | $37.72 | $120.74 |
| Indicator | BSAC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 53.68 |
| Support Level | $34.89 | $89.32 |
| Resistance Level | $35.88 | $101.77 |
| Average True Range (ATR) | 0.84 | 5.51 |
| MACD | 0.17 | 0.81 |
| Stochastic Oscillator | 61.20 | 70.47 |
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.